- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07691515
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma (RAINBOW)
Transcatheter Arterial Chemoembolization in Combination With Tislelizumab Plus Lenvatinib Versus Systemic Cisplatin Plus Gemcitabine in Combination With Tislelizumab for Unresectable Intrahepatic Cholangiocarcinoma: A Phase III, Multicenter, Randomized Controlled Trial
This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of arterially directed therapy in combination with tislelizumab plus lenvatinib compared with gemcitabine and cisplatin (GEMCIS) in combination with tislelizumab as first-line treatment for patients with unresectable intrahepatic cholangiocarcinoma.
Approximately 140 eligible patients with histologically confirmed unresectable intrahepatic cholangiocarcinoma without extrahepatic metastasis will be enrolled and randomized in a 1:1 ratio to receive either TACE plus tislelizumab and lenvatinib or GEMCIS plus tislelizumab. In the TACE-based treatment arm, hepatic arterial infusion chemotherapy with gemcitabine and cisplatin may be administered during or after TACE at the investigator's discretion according to the protocol.
The primary endpoint is overall survival. Secondary endpoints include progression-free survival, time to progression, objective response rate, disease control rate, safety, and quality of life.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Gaojun Teng, MD
- Número de teléfono: +86 13805171500
- Correo electrónico: gjteng@seu.edu.cn
Copia de seguridad de contactos de estudio
- Nombre: Binyan Zhong, MD
- Número de teléfono: +86 15850522044
- Correo electrónico: byzhongir@sina.com
Ubicaciones de estudio
-
-
Guangdong
-
Guangzhou, Guangdong, Porcelana, 510060
- The First Affiliated Hospital, Sun Yat-sen University
-
Contacto:
- Ming Kuang
- Número de teléfono: 020-87755766
- Correo electrónico: kuangm@mail.sysu.edu.cn
-
Contacto:
- Zhenwei Peng
- Correo electrónico: pzhenw@mail.sysu.edu.cn
-
Sub-Investigador:
- Wenzhe Fan
-
Guangzhou, Guangdong, Porcelana, 510317
- Guangdong Second People's Hospital
-
Contacto:
- Chengjiang Xiao
- Número de teléfono: +86 13602808387
- Correo electrónico: Xxx196610@163.com
-
Guangzhou, Guangdong, Porcelana, 510168
- Jinshazhou Hospital of Guangzhou University of Chinese Medicine
-
Contacto:
- Liangliang Qiao
- Número de teléfono: +86 13544539881
- Correo electrónico: 271937316@qq.com
-
Guangzhou, Guangdong, Porcelana, 511400
- The Affiliated Panyu Central Hospital of Guangzhou Medical University
-
Contacto:
- Fuxi Huang
- Número de teléfono: +86 18902299938
- Correo electrónico: Fuxihuang2006@126.com
-
Guangzhou, Guangdong, Porcelana, 524003
- The Second Affiliated Hospital of Guangdong Medical University
-
Contacto:
- Kangshun Zhu
- Número de teléfono: +86 13602864242
- Correo electrónico: Zhksh010@163.com
-
Jiangmen, Guangdong, Porcelana, 529030
- Jiangmen Central Hospital
-
Contacto:
- Yuchuang Liang
- Número de teléfono: +86 13322888181
- Correo electrónico: jmlyc@21cn.com
-
-
Hubei
-
Wuhan, Hubei, Porcelana, 430022
- Wuhan Union Hospital of China
-
Contacto:
- Xuefeng Kan
- Número de teléfono: +86 13545874189
- Correo electrónico: xkliulang1314@163.com
-
-
Hunan
-
Changsha, Hunan, Porcelana, 410013
- The Third XIANGYA Hospital of Central South University
-
Contacto:
- Qi Liang
- Número de teléfono: +86 137 8731 8180
- Correo electrónico: csuliangqi10@163.com
-
Changsha, Hunan, Porcelana, 410011
- The Second Xiangya Hospital of Central South University
-
Contacto:
- Yudong Xiao
- Número de teléfono: +86 136 3740 3027
- Correo electrónico: xiaoyudong222@csu.edu.cn
-
-
Jiangxi
-
Ganzhou, Jiangxi, Porcelana, 341000
- Ganzhou Hospital-Nanfang Hospital, Southern Medical University
-
Contacto:
- Yusheng Song
- Número de teléfono: +86 135 7675 2988
- Correo electrónico: 646993126@qq.com
-
Nanchang, Jiangxi, Porcelana, 330209
- The First Affiliated Hospital of Nanchang University
-
Contacto:
- Junhua Ai
- Número de teléfono: +86 18170936163
- Correo electrónico: aijh0001@163.com
-
-
Shandong
-
Qingdao, Shandong, Porcelana, 266000
- The Affiliated Hospital of Qingdao University
-
Contacto:
- Song Wang
- Número de teléfono: +86 18661805592
- Correo electrónico: derekqyfy@126.com
-
-
Sichuan
-
Chengdu, Sichuan, Porcelana, 610041
- West China School of Medicine/West China Hospital, Sichuan University (WCSM/WCH, SCU)
-
Contacto:
- Chang Liu
- Número de teléfono: +86 18980606382
- Correo electrónico: drliuchang@wchscu.cn
-
-
Zhejiang
-
Hangzhou, Zhejiang, Porcelana, 310022
- Zhejiang Cancer Hospital
-
Contacto:
- Gaojun Teng
- Número de teléfono: +86 0571 - 88122222
- Correo electrónico: gjteng@seu.edu.cn
-
Contacto:
- Binyan Zhong
- Número de teléfono: +86 15850522044
- Correo electrónico: byzhongir@sina.com
-
Sub-Investigador:
- Jiaping Zheng
-
Jinhua, Zhejiang, Porcelana, 321000
- Jinhua Municipal Central Hospital
-
Contacto:
- Xiaogang Hu
- Número de teléfono: +86 135 8866 8173
- Correo electrónico: heartdoctor@163.com
-
Lishui, Zhejiang, Porcelana, 323020
- Lishui Central Hospital
-
Contacto:
- Jiansong Ji
- Número de teléfono: +86 0578-2285888
- Correo electrónico: jjstcty@sina.com
-
Contacto:
- Jianfei Tu
- Correo electrónico: jianfei1133@163.com
-
Ningbo, Zhejiang, Porcelana, 315010
- Ningbo No.2 Hospital
-
Contacto:
- Yunjie Chen
- Número de teléfono: +86 13857877137
- Correo electrónico: a88960317@163.com
-
Ningbo, Zhejiang, Porcelana, 315048
- Ningbo Medical Center Lihuili Hospital
-
Contacto:
- Shengdong Wu
- Número de teléfono: +86 13567886669
- Correo electrónico: 13567886669@139.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Age ≥18 years.
- Histologically confirmed intrahepatic cholangiocarcinoma that is unresectable or recurrent after curative treatment, without extrahepatic metastasis.
- No prior systemic therapy or transarterial interventional therapy for intrahepatic cholangiocarcinoma.
- At least one measurable intrahepatic lesion according to RECIST v1.1.
- ECOG performance status of 0 or 1.
- Child-Pugh class A liver function.
- Life expectancy ≥3 months.
Adequate hematologic, hepatic, renal, and thyroid function within 14 days before study start, defined as:
- Absolute neutrophil count ≥1.5 × 10⁹/L;
- Platelet count ≥75 × 10⁹/L;
- Hemoglobin ≥90 g/L;
- Serum albumin ≥30 g/L;
- Total bilirubin ≤1.5 × upper limit of normal;
- AST and ALT <1.5 × upper limit of normal, and ALP <4 × upper limit of normal;
- TSH <1 × upper limit of normal, with T3 and T4 within the normal range;
- Serum creatinine <1.5 × upper limit of normal and creatinine clearance ≥60 mL/min.
Exclusion Criteria:
- Diffuse infiltrative liver lesions.
- Contraindications to TACE.
- Allergy to intravenous contrast agent.
- pregnant or breastfeeding women, or participants planning pregnancy within 2 years / unwilling to use effective contraception.
- Patients with HIV or syphilis infection.
- Patients with concurrent malignancies or other malignancies within 5 years before enrollment.
- History of allogeneic organ transplantation.
- Severe dysfunction of the heart, kidney, or other organs.
- Severe clinically active infection > grade 2 according to NCI-CTC v5.0.
- Psychiatric illness that may affect the informed consent process; Inability to take oral medications; Participation in another drug clinical trial within 12 months before enrollment.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: TACE Plus Tislelizumab and Lenvatinib
Participants will receive tislelizumab 200 mg intravenously every 3 weeks and oral lenvatinib once daily at a starting dose of 12 mg for body weight ≥60 kg or 8 mg for body weight <60 kg.
TACE will be performed after initiation of lenvatinib and may be repeated based on radiologic response, residual viable tumor, liver function, and investigator assessment.
Both conventional TACE (cTACE) and drug-eluting beads TACE are allowed, and hepatic artery infusion chemotherapy may be added at investigator's discretion.
Treatment will continue until clinical progression, radiologic progressive disease according to RECIST v1.1, completion of 2 years of immunotherapy, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria.
|
Tislelizumab 200 mg intravenously on Day 1 of each 21-day cycle, followed by maintenance tislelizumab every 3 weeks.
Oral lenvatinib once daily, 12 mg for participants with body weight ≥60 kg or 8 mg for participants with body weight <60 kg, with dose modification according to toxicity.
Conventional TACE or drug-eluting bead TACE are allowed.
TACE may be repeated based on imaging assessment every 6 weeks ±7 days and investigator judgment.
Optional hepatic arterial infusion chemotherapy with gemcitabine and cisplatin may be administered during or after TACE at the investigator's discretion according to protocol-defined dose ranges.
|
|
Comparador activo: Gemcitabine-Cisplatin Plus Tislelizumab
Participants will receive cisplatin 25 mg/m² on Day 1 and Day 8, gemcitabine 1000 mg/m² on Days 1 and 8, and tislelizumab 200 mg on Day 1 of each 3-week cycle for up to 8 cycles.
After completion of gemcitabine-cisplatin treatment, participants will continue tislelizumab 200 mg intravenously every 3 weeks.
Treatment will continue until clinical progression, radiologic progressive disease according to RECIST v1.1, completion of 2 years of immunotherapy, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria.
|
Tislelizumab 200 mg intravenously on Day 1 of each 21-day cycle, followed by maintenance tislelizumab every 3 weeks.
Gemcitabine 1000 mg/m² intravenously on Days 1 and 8 of each 21-day cycle, up to 8 cycles.
Cisplatin 25 mg/m² intravenously on Day 1 and Day 8 of each 21-day cycle, up to 8 cycles.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Overall Survival
Periodo de tiempo: From randomization to death from any cause, assessed up to approximately 48 months
|
Overall survival is defined as the time from enrollment/randomization to death from any cause.
Participants who withdraw are lost to follow-up or remain alive at the end of the study will be censored at the date they were last known to be alive.
|
From randomization to death from any cause, assessed up to approximately 48 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Progression-Free Survival
Periodo de tiempo: From randomization to disease progression or death, assessed up to approximately 48 months
|
Defined as the time from randomization to disease progression or death from any cause.
Participants without progression or death will be censored at the last date known to be progression-free.
|
From randomization to disease progression or death, assessed up to approximately 48 months
|
|
Time to Progression
Periodo de tiempo: From randomization to disease progression, assessed up to approximately 48 months
|
Defined as the time from randomization to disease progression.
Participants who die without prior progression, withdraw, are lost to follow-up, or remain progression-free at study end will be censored at the last date known to be progression-free.
|
From randomization to disease progression, assessed up to approximately 48 months
|
|
Objective Response Rate
Periodo de tiempo: Assessed every 6 weeks ±7 days, up to approximately 48 months
|
Defined as the proportion of participants achieving complete response or partial response according to RECIST v1.1.
|
Assessed every 6 weeks ±7 days, up to approximately 48 months
|
|
Disease Control Rate
Periodo de tiempo: Assessed every 6 weeks ±7 days, up to approximately 48 months
|
Defined as the proportion of participants achieving complete response, partial response, or stable disease according to RECIST v1.1.
|
Assessed every 6 weeks ±7 days, up to approximately 48 months
|
|
Incidence of Grade ≥3 Adverse Events
Periodo de tiempo: From first dose of study treatment through 28 days after the last dose of study treatment
|
Defined as the occurrence of grade 3 or higher hematologic or non-hematologic toxicities, graded according to CTCAE v5.0.
|
From first dose of study treatment through 28 days after the last dose of study treatment
|
|
Quality of Life Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Periodo de tiempo: Baseline and during treatment/follow-up, assessed up to approximately 48 months
|
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 is a 30-item questionnaire used to assess health-related quality of life in patients with cancer.
Scores are linearly transformed to a 0 to 100 scale.
For the global health status/quality-of-life scale and functional scales, higher scores indicate better health-related quality of life or functioning.
For symptom scales and single symptom items, higher scores indicate a higher symptom burden or worse symptoms.
|
Baseline and during treatment/follow-up, assessed up to approximately 48 months
|
|
Quality of Life Assessed by the EuroQol Five-Dimension (EQ-5D)
Periodo de tiempo: Baseline and during treatment/follow-up, assessed up to approximately 48 months
|
The EuroQol Five-Dimension Three-Level Questionnaire is a standardized instrument for measuring health-related quality of life.
The descriptive system includes five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Each dimension is scored from 1 to 3, where 1 indicates no problems, 2 indicates some or moderate problems, and 3 indicates extreme problems or inability to perform the activity.
Higher scores in each dimension indicate more severe problems or worse health status.
|
Baseline and during treatment/follow-up, assessed up to approximately 48 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Gaojun Teng, MD, Zhejiang Cancer Hospital
- Investigador principal: Min Kuang, MD, First Affiliated Hospital, Sun Yat-Sen University
- Investigador principal: Jiansong Ji, MD, The Central Hospital of Lishui City
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias
- Neoplasias por tipo histológico
- Neoplasias Glandulares y Epiteliales
- Adenocarcinoma
- Carcinoma
- Colangiocarcinoma
- Cirrosis, familiar, con hipertensión pulmonar
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Químicos inorgánicos
- Compuestos de cloro
- Compuestos de nitrógeno
- Desoxicitidina
- Citidina
- Nucleósidos de pirimidina
- Pirimidinas
- Compuestos de platino
- Gemcitabina
- Cisplatino
- lenvatinib
- tislelizumab
Otros números de identificación del estudio
- RAINBOW 01
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .